The out-licensing of a preclinical GLP-1/GIP dual agonist hands Novo a pipeline asset as rival Eli Lilly leads the branded obesity market and oral options resha

Companies and trade partners including India are parsing the exemption rules for the new branded drug tariffs, which could raise prices on imported medicines.

A new candidate's weight loss exceeds that of existing branded incretins, intensifying the race for more effective obesity treatments.

Positive late-stage readouts revive a program that had been deprioritized, and provide the company a shot at the large anti-VEGF retinal market.

Investor reaction to the longer-term AMT-130 results raises questions about durability of the gene therapy as uniQure approaches regulatory filing.

The court's intervention targets retail pricing power of pharmaceutical companies in a market where cancer medicine costs are a major access issue.

The setback removes one myostatin-based approach from a crowded obesity pipeline that still has many entrants from large drugmakers.

The comparison adds to the evidence gap between the two leading incretin franchises as they compete for market share.

The filing moves a needle-free immunotherapy for peanut allergy closer to a potential US approval.

Counterfeit incretins and unapproved products are spreading in a large market where branded GLP-1 supply remains constrained.

The label expansion broadens the first approved medicine for a condition that previously had limited treatment options in younger patients.

The deal gives Novo access to extended-release drug delivery technology as injectable obesity competition intensifies.

The program aims to widen access to incretin medicines beyond wealthy markets where they are largely used today.

The shift in framing reflects widening use of incretins beyond obesity and diabetes treatment.

The gap highlights regulatory and reimbursement lags that delay access to new medicines in Japan, one of the world's largest drug markets.

The clearance advances an off-the-shelf cell therapy candidate into human testing, a key step for the platform.

The withdrawal removes a product from Merck's anti-infective portfolio amid broader pipeline reshuffling at large drugmakers.

Event and adverse reaction rates from a 210-person study drew investor scrutiny of the antibody's competitive position.